Categories AlphaGraphs, Earnings, Health Care

Earnings: Teva Pharma shrinks Q4 losses, but revenue falls

Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56 billion in the quarter, while net attributable loss shrunk to $2.94 billion or $2.85 per diluted share vs. $11.6 billion or $11.41-a-share in losses a year ago. Non-GAAP profit slipped to $543 million or $0.53 per diluted share, down from last year’s $949 million or $0.93 per share.

The Street expected Teva to post a loss of 53 cents a share on estimated revenue of $4.54 billion. Earnings were more in line with the consensus, but revenue surpassed it by a bit.

Teva Pharmaceuticals fourth quarter earnings infographic

Net non-GAAP adjustments for Teva in the fourth quarter were $3.48billion. Non-GAAP net income and non-GAAP EPS for the fourth quarter were adjusted to exclude a goodwill impairment of $2,73 billion related to International Markets, a $990-million impairment related to the acquisition of Actavis Generics, and other effects and expenses.

 

LOOKING TO 2019

For 2019, Teva sees revenues of $17.0-17.4 billion generating non-GAAP operating income of $3.8-4.2 billion and non-GAAP EPS of $2.20-2.50.

For the coming year, Teva expects continued generic erosion in global COPAXONE sales, touting it to be at about $1.5 billion.

However, the drugmaker expects new launches to offset slight volume decline toNorth America Generics. For International generics, Teva expects an adverse impact in Japan due to NHI price revision and LLP erosion.

 

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Walgreens Boots Alliance set to report earnings next week. Here’s what to expect

Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top